GlassScriptPhysician profile
William H Halama
NPI 1477591071
$9,569.96
in general payments reported to CMS, 2019-2025
36 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $337 · 2021: $945 · 2022: $1,522 · 2023: $1,908 · 2024: $1,935 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,363 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,363.08 |
| Education | $128.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,931.39 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,856.60 | 2019-2025 | |
| Janssen Biotech, INC. | $1,086.45 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $799.82 | 2019-2025 | Entyvio |
| Pfizer INC. | $567.20 | 2019-2025 | |
| Celgene Corporation | $379.60 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $192.44 | 2019-2024 | Linzess |
| Allergan, INC. | $160.81 | 2019 | |
| Merck Sharp & Dohme LLC | $151.92 | 2019-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $136.86 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $122.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Evoke Pharma, INC. | $121.48 | 2022-2023 | Gimoti |
| Celltrion USA INC. | $119.96 | 2024-2025 | Zymfentra, Vegzelma |
| Ardelyx, INC. | $112.78 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $100.18 | 2019-2025 | Sucraid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $96.52 | 2021-2024 | |
| Ucb, INC. | $92.24 | 2019-2020 | |
| Lilly USA, LLC | $75.38 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $66.42 | 2022-2023 | Dupixent |
| Redhill Biopharma INC. | $53.63 | 2021 | |
| Phathom Pharmaceuticals, INC. | $47.33 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $33.55 | 2019-2023 | Rebyota |
| Medtronic USA, INC. | $30.59 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $30.45 | 2022 | |
| Amgen INC. | $26.14 | 2020-2021 | |
| Organon LLC | $20.57 | 2024 | |
| Genzyme Corporation | $20.29 | 2025 | |
| Boston Scientific Corporation | $20.26 | 2023 | Orcapod |
| Concordia Pharmaceuticals INC. | $18.78 | 2019 | |
| Braintree Laboratories, INC. | $15.94 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.80 | 2022 | |
| Exact Sciences Corporation | $15.03 | 2023 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $14.39 | 2020 | |
| Shire North American Group INC | $13.92 | 2019 | |
| Medtronic, INC. | $11.98 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Halama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.